Long noncoding RNAs involved in therapeutic response: implications for cervical cancer drug resistance

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cervical cancer (CC) is a leading cause of cancer death in women globally, particularly in low-income nations with limited screening.
• Current CC treatments using DNA-damaging agents face significant challenges due to drug resistance mechanisms.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their regulatory roles in various cellular processes, including drug resistance.

Purpose of the Study:

• To review the literature on lncRNAs involved in general cancer treatment resistance mechanisms.
• To specifically focus on lncRNAs that mediate treatment resistance in cervical cancer (CC).
• To highlight the potential of lncRNAs as biomarkers and therapeutic targets for resistant CC.

Main Methods:

• Comprehensive literature review of studies on lncRNAs and cancer treatment resistance.
• Focused analysis of lncRNAs implicated in cervical cancer (CC) resistance mechanisms.
• Synthesis of findings to identify knowledge gaps and future research directions.

Main Results:

• lncRNAs play a significant role in diverse drug resistance mechanisms, including drug efflux, DNA repair, apoptosis evasion, and epigenetic alterations.
• While resistance mechanisms share commonalities across cancers, the specific lncRNA regulatory networks differ substantially.
• The specific lncRNAs mediating resistance in cervical cancer (CC) are largely underexplored, presenting a significant research opportunity.

Conclusions:

• lncRNAs are critical regulators of treatment resistance in cervical cancer (CC).
• Identifying CC-specific lncRNAs involved in resistance is crucial for advancing treatment strategies.
• These lncRNAs represent promising candidates for novel diagnostic markers and therapeutic interventions against resistant CC.